Medindia6 天
Inhalable Gene Therapy Trialed for Cystic Fibrosis Patients
Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...
Novel inhalable gene therapy trialed for people with cystic fibrosis
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
GlobalData on MSN8 天
Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim and partners have commenced the Phase I/II LENTICLAIR 1 trial of gene therapy BI 3720931 targeting ...
pharmaphorum8 天
Trial of Boehringer's cystic fibrosis gene therapy imminent
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...
precisionmedicineonline1 天
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
IFLScience on MSN8 天
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical Trials
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...